News

University of Queensland health and medical research projects aimed at improving the nation’s healthcare will benefit from more than $42 million in funding from the National Health and Medical Research Council for 2017.

IMB Industry Fellow Dr Christina Schroeder will tomorrow set sail for the inaugural Homeward Bound program, which is the largest-ever female expedition to Antarctica. The program aims to help women in science to develop their skills in leadership and strategy and raise awareness of the important contributions made by women in STEMM fields.

The young inventor behind a UQ discovery that could benefit patients living with inflammatory diseases has been awarded the 2016 Research Australia Discovery Award.

A $2.3M grant from Australian Cancer Research Foundation (ACRF) is being awarded to UQ IMB today to establish the new ACRF Cancer Ultrastructure and Function Facility (CUFF). The nation-leading facility will provide cutting-edge imaging capabilities for tracking and visualising cancer.

Join us for Superbugs at the Olympics, a free community event hosted by the IMB Centre for Superbug Solutions during Antibiotic Awareness Week.

Researchers from IMB have won first and third prize at Brisbane’s 2016 HealthHack, held 14-16 October at River City Labs. The winning team, Superfriends Against Superbugs, developed an app to track and map the presence of antibiotic-resistant bacteria and rapidly alert clinicians, so they can limit the spread of bacteria and fight an outbreak in real-time.

In a world-first, IMB's Professor Rob Capon and his team are working with industry and the community to implement a discovery that turns cane toads’ own toxin against them, with real potential to eradicate this long-term pest.

By creating the world’s first molecule bank, IMB scientists are working with industry and institutional partners to crowdsource antibiotic compounds, aiming to seek out new antibiotics and prevent the proliferation of drug-resistant superbugs.

A future where no children suffer deadly brain tumours may be within reach, thanks to the vision of a team of researchers from UQ and generous funding from The Kids’ Cancer Project. This funding will enable IMB postdoctoral researcher Dr Laura Genovesi to develop better treatments – and eventually cures – for these devastating conditions.

IMB researchers have been awarded $4.5 million by the Australian Research Council to lead a range of groundbreaking discovery research projects. The ARC announced funding of more than $37 million today for UQ projects spanning fields as diverse as humanities, behavioural science, biomedicine and frontier technologies.

Protagonist Therapeutics, a clinical-stage biopharmaceutical company founded on IMB research, has won Australian Company of the Year at the AusBiotech Industry Excellence Awards.

IMB research has contributed to UQ's top ranking in the Nature Index 2016 Australia and New Zealand.

The future of medicine could be as simple as nibbling a sunflower seed or drinking a cup of tea, with the opening of a new IMB facility, officially opened the Hon Annastacia Palaszczuk, Queensland Premier and Minister for the Arts.

In a world-first, researchers from UQ IMB and University of Washington (UW) have produced tailor-made peptides – an advance expected to help improve drug design and environmentally-friendly pesticides. The team has designed ultra-stable peptide scaffolds that can be used in a range of biotechnological applications.

Does genetic susceptibility predispose women to postpartum depression? Researchers from UQ are calling on Australian mothers to help them find out.

Congratulations to IMB’s Dr Markus Muttenthaler who received the Miklós Bodanszky Award for his outstanding contributions to peptide science. 

Thanks to a $1.3 million state government research grant, IMB’s Dr Nathan Palpant has partnered with Professor John Fraser at The Prince Charles Hospital to develop next generation medical treatments to tackle heart disease, which claims the life of one Australian every 12 minutes.

Paralympian Chris Bond was 19 when a severe bacterial infection in his bowel spread through his body and sent him into septic shock. Today, on World Sepsis Day (13 September), Chris is working with IMB's Community for Open Antimicrobial Drug Discovery (CO-ADD) to bring attention to the multidrug-resistant bacteria that nearly took his life.

Inflazome Ltd, a company founded on research from The University of Queensland (UQ) and Trinity College Dublin, has closed a Series A financing round of up to €15 million (A$22 million).

IMB’s Mathilde Desselle has won the Queensland Women in Technology (WiT) InfoTech Professional Award for her leadership of biomedical research programs and facilities in the fields of genomics, bioinformatics and drug discovery.